The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer

Carcinogenesis

Volumn 28, Issue 5, 2007, Pages 932-939

  Kim, Caroline S ^b   Ying, Hao ^b   Willingham, Mark C ^a   Cheng, Sheue Yann ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; KI 67 ANTIGEN; P21 ACTIVATED KINASE; RETINOBLASTOMA PROTEIN; SECURIN; TRANSCRIPTION FACTOR E2F; VASCULOTROPIN; PITUITARY TUMOR TRANSFORMING PROTEINS; PITUITARY TUMOR-TRANSFORMING PROTEINS; THYROID HORMONE RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HISTOPATHOLOGY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; THYROID FOLLICULAR CANCER; TUMOR GROWTH; ANIMAL; CELL CULTURE; DISEASE COURSE; DISEASE MODEL; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID TUMOR; VASCULARIZATION;

ANIMALS; CARCINOMA, PAPILLARY, FOLLICULAR; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, THYROID HORMONE; THYROID GLAND; THYROID NEOPLASMS;

EID: 34447109798     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl231     Document Type: Article

References (32)

1. Zou, H. et al. (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science, 288, 418-422.
2. Ramaswamy, S. et al. (2003) A molecular signature of metastasis in primary solid tumors. Nat. Genet., 33, 49-54.
3. Pei, L. et al. (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol., 11 433-441.
4. Zhang, X. et al. (1999) Structure, expression and function of human pituitary tumor transforming gene (PTTG). Mol. Endocrinol., 13, 156-166.
5. Kim, D. et al. (2005) Pituitary tumor transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene, 24, 4861-4866.
6. Heaney, A.P. et al. (2000) Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet, 355, 716-719.
7. Ishikawa, H. et al. (2001) Human pituitary tumor-transforming gene induces angiogenesis. J. Clin. Endocrinol. Metab., 86, 867-874.
8. Jallepalli, P.V. et al. (2001) Securin is required for chromosomal stability in human cells. Cell, 105, 445-457.
9. Hamid, T. et al. (2004) PTTG/securin activates expression of p53 and modulates its function. Mol. Cancer, 3, 18.
10. Zhou, C. et al. (2005) Overexpression of human pituitary tumor transforming gene (hPTTG) is regulated by beta-catenin/TCF pathway in human esophageal squamous cell carcinoma, Int. J. Cancer, 113 891-898.
11. Mu, Y.M. et al. (2003) Human pituitary tumor transforming gene (hPTTG) inhibits human lung cancer A549 cell growth through activation of p21 (WAF1/CIO1). Endocr. J., 50, 771-781.
12. Bernal, J.A. et al. (2002) Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat. Genet., 32, 306-311.
13. Yu, R. et al. (2000) Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: Evidence from live cell imaging. Mol. Endocrinol., 14, 1137-1146.
14. Chen, L. et al. (2000) Identification of the human pituitary tumor transforming gene (hPTTG) family: Molecular structure, expression and chromosomal localization. Gene, 248, 41-50.
15. Wang, Z. et al. (2001) Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol. Endocrinol., 15, 1870-1879.
16. -/- mice is protective for Rb+/- pituitary tumorigenesis. Mol. Endocrinol., 19, 2371-2379.
17. Donangelo, I. et al. (2006) PTTG over-expression facilitates pituitary tumor development. Endocrinology, 147, 4781-4791.
18. Heaney, A.P. et al. (2001) Transforming events in thyroid tumorigenesis and their association with follicular lesions. J. Clin. Endocrinol. Metab., 86, 5025-5032.
19. Kim, D.S. et al. (2006) Pituitary tumor transforming gene (PTTG) regulates multiple downstream angiogenic genes in thyroid cancer. J. Clin. Endocrinol. Metab., 91, 1119-1128.
20. Suzuki, H. et al. (2003) Compensatory role of thyroid hormone receptor (TR)α1 in resistance to thyroid hormone: Study in mice with a targeted mutation in the TRβ gene and deficient in TRα1. Mol. Endocrinol., 17, 1647-1655.
21. Ying, H. et al. (2003) Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis, 24, 1467-1479.
22. Kaneshige, M. et al. (2000) Mice with a targeted mutation in the thyroid hormone β receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc. Natl Acad. Sci. USA, 97, 13209-13214.
23. Kim, C.S. et al. (2005) AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology, 146 4456-4464.
24. Furumoto, H. et al. (2005) An unliganded thyroid hormone β receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/ E2F pathway and induces pituitary tumorigenesis. Mol. Cell. Biol., 25, 124-135.
25. Zitzmann, S. et al. (2002) Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res., 62, 5139-5143.
26. Ying, H. et al. (2005) Dual functions of the steroid hormone receptor coactivator 3 in modulating resistance to thyroid hormone. Mol. Cell. Biol., 25, 7687-7695.
27. Zavacki, A.M. et al. (2005) Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse. Endocrinology, 146, 1568-1575.
28. Suzuki, H. et al. (2002) Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: A mouse model of thyroid carcinogenesis. Thyroid, 12, 963-969.
29. Yamamoto, S. et al. (2005) Increased expression of valosin-containing protein (p97) is correlated with disease recurrence in follicular thyroid cancer. Ann. Surg. Oncol., 12, 925-934.
30. Abbud, R.A. et al. (2005) Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol. Endocrinol. 19, 1383-1391.
31. Ramsden, J.D. et al. (2005) Complete inhibition of goiter in mice requires combined gene therapy modification of angiopoietin, vascular endothelial growth factor, and fibroblast growth factor signaling. Endocrinology, 146, 2895-2902.
32. Kim, B.W. et al. (2003) Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J. Clin. Endocrinol. Metab., 88, 594-598.